Rapalogs Potential as Practical Alternatives to Rapamycin

Rapalogs Potential as Practical Alternatives to Rapamycin Contemporary mTOR inhibitor scaffolds to diseases breakdown: A patent review (2015–2021) Targeting mTOR for fighting diseases: A revisited review of mTOR inhibitors Rapamycin analogs with reduced systemic exposure Generation of Novel Rapamycin Structures by Microbial Manipulations. Synthesis and biological evaluation of rapamycin-derived, next generation small molecules Discovery of 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a Potent, Selective, and Orally Available Mammalian Target of Rapamycin (mTOR) Inhibitor for Treatment of Cancer Isolation and Structure of Homotemsirolimuses A, B, and C Synthesis and bioactivity of photolabile sirolimus (rapamycin) analogs Potent, Selective, and Orally Bioavailable Inhibitors of the Mammalian Target of Rapamycin Kinase Domain Exhibiting Single Agent Antiproliferative Activity